{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T15:10:27Z","timestamp":1726413027671},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00393-020-00808-0","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T18:03:31Z","timestamp":1589306611000},"page":"516-522","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapie der Riesenzellarteriitis: Was ist in der Pipeline?","Treatment of giant cell arteritis: what is in the pipeline?"],"prefix":"10.1007","volume":"79","author":[{"given":"J. U.","family":"Holle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Moosig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"808_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/BF03401699","volume":"3","author":"A Brack","year":"1997","unstructured":"Brack\u00a0A, Geisler\u00a0A, Martinez-Taboada\u00a0VM et al (1997) Giant cell vasculitis is a\u00a0T cell-dependent disease. Mol Med 3:530\u2013543","journal-title":"Mol Med"},{"issue":"suppl 10","key":"808_CR2","first-page":"2689","volume":"71","author":"M Cid","year":"2019","unstructured":"Cid\u00a0M, Gandhi\u00a0R, Corbera-Bellalta\u00a0M et al (2019) GM-CSF pathway signature identified in temporal artery biopsies of patients with giant cell arteritis. Arthritis Rheumatol 71(suppl 10):2689","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"808_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","volume":"48","author":"R Conway","year":"2018","unstructured":"Conway\u00a0R, O\u2019Neill\u00a0L, Gallagher\u00a0P et al (2018) Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. Semin Arthritis Rheum 48(3):523\u2013528","journal-title":"Semin Arthritis Rheum"},{"key":"808_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng\u00a0J, Younge\u00a0BR, Olshen\u00a0RA et al (2010) Th17 and Th1T-cell responses in giant cell arteritis. Circulation 121:906\u2013915","journal-title":"Circulation"},{"issue":"12","key":"808_CR5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru\u00a0N, van der Goes\u00a0M, Jacobs\u00a0JWG et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72(12):1095\u20131013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"808_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich\u00a0B, Augeda\u00a0A, Monti\u00a0S et\u00a0al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19\u201330","journal-title":"Ann Rheum Dis"},{"key":"808_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"GS Hoffman","year":"2002","unstructured":"Hoffman\u00a0GS, Cid\u00a0MC, Hellmann\u00a0DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309\u20131318","journal-title":"Arthritis Rheum"},{"key":"808_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover\u00a0JA, Hernandez-Garcia\u00a0C, Morado\u00a0IC et al (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone: a\u00a0randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106\u2013114","journal-title":"Ann Intern Med"},{"key":"808_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"C Langford","year":"2017","unstructured":"Langford\u00a0C, Cuthbertson\u00a0D, Ytterberg\u00a0SR et al (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69:837\u2013845","journal-title":"Arthritis Rheumatol"},{"key":"808_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jbspin.2013.06.004","volume":"81","author":"KH Ly","year":"2014","unstructured":"Ly\u00a0KH, Stirnemann\u00a0J, Liozone\u00a0E et al (2014) Interleukin\u20111 blockade in refractory giant cell arteritis. Joint Bone Spine 81:76\u201378","journal-title":"Joint Bone Spine"},{"issue":"8","key":"808_CR11","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr\u00a0AD, Jover\u00a0JA, Spiera\u00a0RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789\u20132797","journal-title":"Arthritis Rheum"},{"issue":"6","key":"808_CR12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl\u00a0C, Bijlsma\u00a0JW, de Wit\u00a0M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75(6):952\u2013957","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"808_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S et al (2017) Trial of tocilizumab in giant-cell arteritis. N\u00a0Engl J Med 377(4):317\u2013328","journal-title":"N Engl J Med"},{"issue":"suppl 10","key":"808_CR14","first-page":"0808","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone\u00a0JH, Bao\u00a0M, Han\u00a0J et al (2019) Long-term outcome of Tocilizumab for patients with giant cell arteritis: results from part 2 of a\u00a0randomized controlled phase 3 trial. Arthritis Rheumatol 71(suppl 10):808","journal-title":"Arthritis Rheumatol"},{"key":"808_CR15","first-page":"495","volume":"19","author":"RF Spiera","year":"2001","unstructured":"Spiera\u00a0RF, Mitnick\u00a0HJ, Kupersmith\u00a0M et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495\u2013501","journal-title":"Clin Exp Rheumatol"},{"key":"808_CR16","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger\u00a0PM, Adler\u00a0S, Kuchen\u00a0S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a\u00a0phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927","journal-title":"Lancet"},{"key":"808_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1196\/annals.1358.023","volume":"1062","author":"CM Weyand","year":"2015","unstructured":"Weyand\u00a0CM, Ma-Krupa\u00a0W, Pryshchep\u00a0O et al (2015) Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci 1062:195\u2013208","journal-title":"Ann N Y Acad Sci"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00808-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00808-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T23:50:15Z","timestamp":1620777015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00808-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00808-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"12 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.U.\u00a0Holle und F.\u00a0Moosig haben Referentenhonorare Firma Chugai erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}